|
Effect of early blood counts on overall survival (OS) following glasdegib + LDAC in newly diagnosed AML: BRIGHT AML 1003 post hoc analysis. |
|
|
Consulting or Advisory Role - Abbvie; Agios; Amgen; Astellas Pharma; Celyad; Daiichi Sankyo; Jazz Pharmaceuticals; Kite/Gilead; Kura Oncology; Macrogenics; Pfizer; PTC Therapeutics; Stemline Therapeutics |
Speakers' Bureau - Jazz Pharmaceuticals; Stemline Therapeutics |
|
|
Honoraria - Novartis; Pfizer |
Consulting or Advisory Role - Janssen Oncology; Novartis; Pfizer; Stemline Therapeutics |
Research Funding - Astellas Pharma (Inst); Bayer (Inst); BerGenBio (Inst); Daiichi Sankyo (Inst); Novartis (Inst); Pfizer (Inst) |
|
|
Consulting or Advisory Role - Celgene; Millennium; Syros Pharmaceuticals |
Research Funding - Pfizer (Inst); Takeda (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Pfizer |
|
Research Funding - Amgen; Pfizer |
|
|
|
Stock and Other Ownership Interests - Pfizer |
|
|
|
Stock and Other Ownership Interests - Pfizer |
|
|
|
Stock and Other Ownership Interests - Pfizer |
|
|
|
Stock and Other Ownership Interests - Pfizer |
|
|
Consulting or Advisory Role - Amphivena Therapeutics; Astellas Pharma; Bio-Path Holdings, Inc; BiolineRx; Bristol-Myers Squibb; Daiichi Sankyo; Jazz Pharmaceuticals; Novartis; Pfizer; Takeda |
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Immunogen (Inst); Jazz Pharmaceuticals (Inst); Merus (Inst); Novartis (Inst); Pfizer (Inst); Sun Pharma (Inst); Takeda (Inst); Tolero Pharmaceuticals (Inst); Trovagene (Inst) |